Academic Appointments
- Professor of Neurology (in the Gertrude H. Sergievsky Center and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain) at CUMC
Lawrence Honig, MD, PhD, is a Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons (New York, NY), in the Department of Neurology (Division of Aging and Dementia), Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Gertrude H. Sergievsky Center. He is Director of the Clinical Core of the Alzheimer's Disease Research Center at Columbia University.
Dr. Honig obtained his MD medical degree from the University of Miami (Miami, Florida), and his PhD from the University of California at Berkeley (Berkeley, California). He underwent postgraduate internship in Medicine and residency in Neurology training at Stanford University Medical Center (California). He served on the faculty of the Neurology departments at Stanford University Medical Center, and then at the University of Texas Southwestern Medical Center in Dallas, prior to his arrival at Columbia University in the year 2000. His research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at NewYork-Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.
Dr. Honig's research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at New York Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.
Departmental Appointments
- Department of Neurology
Division of Aging and Dementia
Board Certifications
- Neurology
Areas of Expertise
- Behavioral Disorder
- Dementia
- Memory Disorder
Languages Spoken
(in addition to English)
- Spanish
- French
Education and Training
- University of Miami School of Medicine
- Internship: Stanford University School of Medicine
- Residency: Stanford University School of Medicine
Locations
Neurological Institute of New York
710 West 168th Street
New York, NY 10032- Phone:
- (212) 305-6939
- For new and current patient appointments, call:
- (212) 305-6939
- Fax:
- (212) 305-1145
Centers / Institutes / Programs
- Gertrude H. Sergievsky Center
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Provider Affiliations
- NewYork-Presbyterian/Columbia
Insurance Programs
Please contact the provider's office directly to verify that your particular insurance is accepted.
- Aetna [EPO, HMO, Medicare Managed Care, NY Signature, NYP Employee Plan, POS, PPO, Signature Administrators, Student Health]
- AgeWell [Medicare Managed Care, Special Needs Plan]
- Capital District Physician Health Plan [Capital District Physician Health Plan]
- Cigna [EPO, Great West, HMO, POS, PPO]
- Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
- Empire Blue Cross Blue Shield [EPO, Medicare Managed Care, PPO]
- Local 1199 [Local 1199]
- MagnaCare [MagnaCare]
- MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
- Oxford Health Plans [Freedom, Liberty]
- UnitedHealthcare [Columbia University Employee Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
This provider accepts new patients
Appointment Phone Number: (212) 305-6939
Links
NIH Grants
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OFPLACEBO GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Feb 21 2019 - Feb 21 2024
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED, STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF E2027 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES. [DELPHIA] (P&S Industry Clinical Trial)
Nov 27 2018 - Nov 27 2023
PHASE 2 EXTENSION OF STUDY M15-562 TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ABBV-8E12 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY (PSP) (P&S Industry Clinical Trial)
Oct 2 2018 - Oct 2 2023
NEUROANATOMICAL ASSOCIATIONS WITH THE FACTOR STRUCTURE UNDERLYING NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER S DISEASE (Federal Gov)
Sep 30 2018 - May 31 2023
A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Mar 7 2018 - Mar 7 2023
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER?S DISEASE (P&S Industry Clinical Trial)
Feb 22 2018 - Feb 22 2023
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Jan 29 2018 - Jan 29 2023
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUSLY ADMINISTERED BMS-986168 IN PARTICIPANTS WITH PROGRESSIVE SUPRANUCLEAR PALSY (P&S Industry Clinical Trial)
Jan 11 2018 - Jan 11 2023
OPEN LABEL EXTENSION STUDY FOR CONTINUED SAFETY AND EFFICACY EVALUATION OF AZELIRAGON IN PATIENTS WITH MILD ALZHEIMER''S DISEASEAAAR5985 - TTP488-303 (P&S Industry Clinical Trial)
Jan 4 2018 - Jan 4 2023
COGNITIVE ANS NEURAL MECHANISMS OF THE ACCELERATED AGING PHENOTYPE IN PTSD (Federal Gov)
Sep 1 2017 - Jul 31 2022
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE DOSE STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ABBV-8E12 IN PROGRESSIVE SUPRANUCLEAR PALSY (P&S Industry Clinical Trial)
Jun 23 2017 - Jun 23 2022
A LONG-TERM EXTENSION STUDY OF THE SAFETY AND TOLERABILITY OF RVT-101 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES (DLB) (P&S Industry Clinical Trial)
May 10 2017 - May 10 2022
APATHY AND NEGATIVE SYMPTOMS IN ALZHEIMER S DISEASE: INVESTIGATION OF THE PROLINE*COMT INTERACTION FOR SYMPTOM TARGETING TO POSITIVELY IMPACT QUALITY OF LIFE (Federal Gov)
Sep 15 2018 - Sep 14 2021
TARGETING LEWY BODY SPECIFIC PATHOLOGY USING BIOMARKERS (Federal Gov)
Sep 30 2016 - Aug 31 2021
CENTER OF EXCELLENCE IN ALZHEIMER DISEASE (NYS) (NY State Gov)
Jul 1 2016 - May 31 2021
ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)
Jun 15 2015 - May 31 2021
APATHY IN ALZHEIMER S DISEASE: INVESTIGATION OF THE INTERACTION BETWEEN PROLINE AND COMT FOR TREATMENT TARGETING TO POSITIVELY IMPACT QUALITY OF LIFE (Federal Gov)
Aug 15 2018 - Apr 30 2021
BIOMARKERS OF ALZHEIMER S DISEASE IN ADULTS WITH DOWN SYNDROME (Federal Gov)
Sep 30 2015 - Apr 30 2021
ASSESSMENT AND CHARACTERIZATION OF NAMING IN OLDER ADULTS WITH EPILEPSY (Federal Gov)
Apr 1 2014 - Mar 31 2021
LONG LIFE FAMILY STUDY: COLUMBIA UNIVERSITY (Federal Gov)
May 1 2014 - May 31 2020
THE LONG LIFE FAMILY STUDY: COLUMBIA UNIVERSITY (Federal Gov)
Jun 1 2019 - Mar 31 2020
A PHASE IB, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED, DOUBLE-BLIND,PARALLEL-ARM, MULTIPLE-DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, ANDPHARMACOKINETICS OF INTRAVENOUS CRENEZUMAB ADMINISTERED IN PATIENTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Mar 16 2015 - Mar 16 2020
A MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) EFFECTS OF POSIPHEN IN THE SUBJECT (Federal Gov)
Oct 1 2017 - Feb 29 2020
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LU AE58054 AS ADJUNCTIVE TREATMENT TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS (P&S Industry Clinical Trial)
Dec 3 2014 - Dec 3 2019
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 26-WEEK, PHASE 3 STUDY OF TWO DOSES OF EVP-6124 OR PLACEBO IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE CURRENTLY OR PREVIOUSLY RECEIVING AN (P&S Industry Clinical Trial)
Jun 16 2014 - Jun 16 2019
EARLY ONSET AD CONSORTIUM - THE LEAD STUDY (LEADS) (Federal Gov)
Sep 30 2018 - May 31 2019
LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) (Federal Gov)
Sep 30 2014 - May 31 2019
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 18-MONTH SAFETY AND EFFICACY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH MILD ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Mar 31 2014 - Mar 31 2019
EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMER''S DISEASE: SOLANEZUMAB (LY2062430) VERSUS PLACEBO (P&S Industry Clinical Trial)
Feb 14 2014 - Feb 14 2019
IMAGING DEMENTIA EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY: A COVERAGE WITH EVIDENCE DEVELOPMENT LONGITUDINAL COHORT STUDY (Private)
Jan 1 2016 - Dec 31 2018
A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF 2 POTENTIAL DISEASE MODIFYING THERAPIES IN INDIVIDUALS AT RISK FOR AND WITH DOMINANTLY INHERITED ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Dec 23 2013 - Dec 23 2018
LBDA RESEARCH CENTERS OF EXCELLENCE (RCOE) PROGRAM (Private)
Oct 1 2017 - Sep 30 2018
EARLY ONSET ALZHEIMER S DISEASE CONSORTIUM (Federal Gov)
Sep 15 2017 - Aug 31 2018
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869G AND ABE4955G IN PATIENTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Jul 23 2013 - Jul 23 2018
A PHASE 2, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL AMYLOID ANGIOPATHY (P&S Industry Clinical Trial)
Jul 18 2013 - Jul 18 2018
GENENTECH ABE4869G (P&S Industry Clinical Trial)
Oct 10 2011 - Oct 10 2016
ACC-001-ALZ-2001 (P&S Industry Clinical Trial)
Sep 29 2011 - Sep 29 2016
H8A-MC-LZAO (P&S Industry Clinical Trial)
Aug 25 2011 - Aug 25 2016
A PHASE 2,RANDOMIZED DOUBLE-BLIND,PLACEBO-CONTROLLED,STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE TREATMENT OF PRGRE (P&S Industry Clinical Trial)
Nov 4 2010 - Nov 4 2015
ALZHEIMER S DISEASE NEUROIMAGING INITIATIVE, (ADNI) (Federal Gov)
Jun 1 2005 - Aug 31 2015
NATIONAL ALZHEIMER S COORDINATING CENTER (Federal Gov)
Jul 1 2014 - Jun 30 2015
ELI LILLY-H6L-MCLFBF (P&S Industry Clinical Trial)
Jun 30 2010 - Jun 30 2015
A PHASE 3 EXTENSION, MULTICENTER, DOUBLE-BLIND, LONG TERM SAFETY AND TOLERABILITY TREATMENT TRIAL OF BAPINEUZUMAB (P&S Industry Clinical Trial)
Mar 5 2010 - Mar 5 2015
A LONG-TERM FOLLOW-UP STUDY OF ORAL ELND005(AZD-103) IN SUBJECTS WITH ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)
Mar 4 2010 - Mar 4 2015
MAGNETIC RESONANCE SPECTROSCOPY (MRS) TO ASSESS PROGRESSION OF ALZHEIMER DISEASE (AD) (Private)
Aug 1 2012 - Jan 31 2015
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF THE SAFETY TOLERABILITY PHARMACODYNAMIC (P&S Industry Clinical Trial)
Jan 8 2010 - Jan 8 2015
PROTOCOL-H8A-MC-LZAM: EFFECT OF LY2062430, AN ANTI-AMYLOID BETA MONOCIONAL ANTIBODY ON THE PROGRESSION OF ALZHEIMERS (P&S Industry Clinical Trial)
Nov 2 2009 - Nov 2 2014
AN OPEN-LABEL,NON RANDOMIZED, MULTICENTER STUDY TO OPTIMIZE IMAGE ASSESSMENT AND EVALUATE THE EFFICACY AND SAFETY OF BAY (P&S Industry Clinical Trial)
Jul 1 2009 - Jul 1 2014
SUPPLEMENTAL POSITRON EMISSION TOMOGRAPHY SUBSTUDY PROTOCOL TO CLINICAL RESEARCH PROTOCOLS ELN115727-301-302 (P&S Industry Clinical Trial)
Jun 30 2009 - Jun 30 2014
EARLY AD DETECTION WITH ASL MRI & COVARIANCE ANALYSIS (Federal Gov)
Sep 1 2007 - Jun 30 2014
NATIONAL ALZHEIMER S COORDINATING CENTER (NACC) - YEAR 15 (Federal Gov)
Jul 1 1999 - Jun 30 2014
NATIONAL ALZHEIMER S COORDINATING CENTER (NACC) - YR 15 (Federal Gov)
Jul 1 1999 - Jun 30 2014
QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME (Federal Gov)
Mar 1 2000 - May 31 2014
ELAN -- ELND005 AD20 (P&S Industry Clinical Trial)
Apr 28 2008 - Oct 31 2013
CARDIOVASCULAR DISEASES: DEPRESSION AND TELOMERE LENGTH (Federal Gov)
Sep 1 2008 - May 31 2013
LILLY LFAN (P&S Industry Clinical Trial)
Aug 14 2008 - Mar 31 2013
LP PATIENT EXPERIENCE SURVEY (Private)
Oct 18 2011 - Oct 17 2012
EPIDEMIOLOGY OF MENOPAUSE AND DEMENTIA IN DOWN SYNDROME (Federal Gov)
Apr 1 1998 - Jul 31 2012
COMBINED CSF BIOMARKERS AND GBA GENOTYPE FOR DIAGNOSIS OF LB D (Private)
Mar 1 2010 - Jun 30 2012
NATIONAL ALZHEIMER''S COORDINATING CENTER (NACC) YEAR 10 (Federal Gov)
Jul 1 1999 - Jun 30 2012
NATIONAL ALZHEIMER''S COORDINATING CENTER (NACC) YEAR 11 (Federal Gov)
Jul 1 1999 - Jun 30 2012
NATIONAL ALZHEIMER''S COORDINATING CENTER (NACC) YEAR 11 (Federal Gov)
Jul 1 1999 - Jun 30 2012
CHANGES IN TELOMERE LENGTH AND THE RISK OF ALZHEIMER DISEASE (Private)
Nov 1 2008 - Oct 31 2011
PREDICTORS OF SEVERITY IN ALZHEIMER''S DISEASE (Federal Gov)
Feb 1 1989 - Aug 31 2011
DEVELOPMENT OF NOVEL BIOMARKERS FOR ALZHEIMER''S DISEASE (Federal Gov)
May 7 2009 - Jan 31 2010
